Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free Xeljanz blood clot injury cases. Here at Leading Justice, we can customize your firm’s Xeljanz blood clot injury advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Xeljanz injury advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all our contacts, which means any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Xeljanz and side effects like pulmonary embolism, deep vein thrombosis and wrongful death, Leading Justice will increase your firm’s Xeljanz injury caseload. If you are interested in helping victims of Xeljanz side effects, our direct advertising strategies and extensive consumer reach at Leading Justice gives you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. Our experience working with plaintiff law firms helps us recognize a great case when we see one, but we will customize our Xeljanz blood clot injury intake specifications to the exact criteria you are seeking. So, if your firm has specific Xeljanz qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Xeljanz injury data with zero chance of fraud.
Xeljanz Blood Clot Injury Litigation
Xeljanz is an oral immunosuppressant medication approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ulcerative colitis in adults. The drug is available in a high 10mg, twice-daily dose (typically prescribed for ulcerative colitis) and a lower 5mg, twice-daily dose (typically prescribed for RA and PSA). Xeljanz falls into the category of drugs known as Janus kinase (JAK) inhibitors, which work by blocking the activity of enzymes called Janus kinases. An overactive immune system is what contributes to RA, PSA and ulcerative colitis and by acting on these enzymes and decreasing the activity of the immune system, Xeljanz can help reduce the painful inflammation characteristic of these chronic autoimmune diseases.
Xeljanz has already been on the market in the United States for seven years. Upon approving Xeljanz in 2012, the FDA commissioned a postmarketing study to evaluate the risk of cancer, heart problems and opportunistic infections in patients treated with Xeljanz. In 2019, after conducting an interim analysis of the results of the ongoing clinical trial, the FDA issued a safety communication warning that there was an increased risk of blood clots in the lungs and death in RA patients taking the 10mg, twice-daily dose of Xeljanz. Later that year, the FDA issued another safety communication indicating that the agency had approved a new Boxed Warning highlighting the increased risk of blood clots and death associated with the higher dose of Xeljanz. According to the reports, patients taking Xeljanz may face an increased risk of dangerous blood clots in the lungs and deep veins of the body, which can lead to a potentially life-threatening venous thromboembolic event (VTE) like pulmonary embolism (PE) or deep vein thrombosis (DVT).